Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000423325 | SCV000532516 | likely benign | not provided | 2020-12-03 | criteria provided, single submitter | clinical testing | |
Blueprint Genetics | RCV000423325 | SCV000927213 | uncertain significance | not provided | 2017-03-31 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000423325 | SCV002400626 | benign | not provided | 2024-12-03 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002374697 | SCV002624416 | likely benign | Cardiovascular phenotype | 2019-09-25 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Prevention |
RCV004533104 | SCV004740189 | likely benign | ALPK3-related disorder | 2019-09-17 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |